Peptide News Digest

Wegovy Pill EU CHMP Approval, Retatrutide TRIUMPH-1 Analyst Dysesthesia Signal, Bicycle Duravelo-2 Phase 2 65% ORR, Hims $350M Convertible, BriaCell 16.6mo OS, CRAB CRAC Channel Peptides

Wegovy pill EU CHMP positive opinion, retatrutide TRIUMPH-1 analyst dysesthesia signal, Bicycle Duravelo-2 Phase 2 65% ORR, Hims $350M convertible, BriaCell 16.6mo OS.

10 stories · Covering regulatory, industry, clinical-trials, research

Editor's Note

Friday digest split between Europe-side regulatory progress on the Wegovy pill, the day-after analyst reaction to Thursday's TRIUMPH-1 readout, fresh ASCO 2026 specifics from the May 21 abstract embargo lift, and a wave of non-GLP-1 peptide-research papers. Novo Nordisk announced EMA CHMP positive opinion for the once-daily oral semaglutide 25 mg this morning, paving the way for Wegovy pill EU launches in H2 2026 with the SELECT MACE-reduction labeling carried over. The CHMP opinion confirms the international rollout flagged at the May 18 CNBC piece is moving on schedule. On the TRIUMPH-1 follow-on cycle, LLY traded up ~1% premarket Thursday and analyst commentary settled into a split read: William Blair flagged that retatrutide's 11.3% high-dose discontinuation rate plus the dysesthesia signal (12.5% at 12 mg, not reported in Phase 2) confines the drug to higher-BMI patients with tirzepatide remaining the volume agent, while Pharma Intelligence framed the data as 'very impressive' pending ADA 2026 full data presentation. Bicycle Therapeutics formally released Duravelo-2 Phase 2 specifics this morning — 65% ORR (17/26) regardless of confirmation and 58% BICR-confirmed ORR (15/26) at 27-week cutoff in the optimal-dose combination cohort. Hims & Hers priced an upsized $350M zero-coupon convertible senior notes offering due 2032 on May 18 settling May 21, with proceeds backing the Eucalyptus acquisition and international expansion. On the non-GLP-1 research side, three Nature Communications papers landed worth tracking: AMPLiT-driven identification of antimicrobial peptides from ancient gut microbiomes (human coprolite metagenomes); CRAB engineered peptide inhibitors targeting CRAC channel STIM1-ORAI signaling for precision immune modulation (Texas A&M Health team); and a Journal of Peptide Science note on WDGL — a tetrapeptide derived from Ulva prolifera that activates the Keap1-Nrf2 antioxidant pathway. BriaCell's formal ASCO 2026 follow-on press release this morning specified the 16.6-month Bria-IMT median overall survival number with the Phase 3 formulation. The Glucagon-Like Peptide-1 Agonists Weight Loss Drugs Market Report published May 21 projects the segment growing from $15.5B in 2025 to $18.02B in 2026 (16.3% CAGR).

Regulatory

Wegovy Pill EU CHMP Positive Opinion (May 22): EMA Recommends Marketing Authorization for Once-Daily Oral Semaglutide 25 mg With SELECT MACE-Reduction Labeling

Novo Nordisk announced on May 22 that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency adopted a positive opinion recommending marketing authorization of Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain long-term weight reduction. The recommendation includes data from SELECT in the label — the cardiovascular outcomes trial that documented a 20% major adverse cardiovascular event reduction with injectable Wegovy. The CHMP opinion is the first oral GLP-1 EU approval recommendation for weight management. OASIS 4 Phase 3 data anchoring the filing: 16.6% mean weight loss in adults with obesity or overweight plus one comorbidity, comparable to injectable Wegovy 2.4 mg. Novo plans to launch the pill in select non-US markets in H2 2026, with UK, Germany, and Denmark previously flagged as the first international launches (CNBC May 18). The CHMP opinion confirms the international expansion path Novo's EVP Larsen described.

#novo-nordisk #wegovy-pill #ema-chmp #oral-semaglutide #select-mace #international-launch #eu-approval
Industry

TRIUMPH-1 Analyst Reaction (May 22): LLY +1% Premarket, William Blair Sees High-BMI Confinement on 11.3% Discontinuation + Dysesthesia Signal, Mahmood 'Very Impressive' Pending ADA Data

Day-after analyst reaction to Lilly's May 21 TRIUMPH-1 topline split between efficacy enthusiasm and tolerability caution. LLY shares rose roughly 1% in Thursday premarket trading. William Blair noted that retatrutide's 11.3% discontinuation rate on 12 mg plus the dysesthesia signal (skin tingling, 12.5% of 12 mg participants — a finding not reported in Phase 2 data) probably confines the drug to higher-BMI patient populations, with tirzepatide remaining the volume agent at the moderate-BMI tier. BMO Capital Markets specifically flagged the dysesthesia signal as worth monitoring in subsequent readouts and the TRIUMPH-4 follow-on detail. Manak Mahmood at Pharma Intelligence framed the data as 'very impressive' but noted ADA 2026 full data presentation in two weeks will be critical for the obesity-market positioning. The GI side-effect profile at 12 mg — nausea 42.4%, vomiting 25.3%, diarrhea 32.0% — is the tolerability gap that prescribers will weigh against the efficacy gain over tirzepatide.

#retatrutide #triumph-1 #lly-stock #william-blair #bmo #dysesthesia #analyst-reaction
Clinical Trials

Bicycle Therapeutics Duravelo-2 Phase 2 Detailed Data (May 22): 65% ORR (17/26) and 58% BICR-Confirmed ORR (15/26) at 27-Week Cutoff for Zelenectide Pevedotin + Pembrolizumab in 1L Urothelial Cancer

Bicycle Therapeutics' formal post-ASCO 2026 press release Friday morning specified the headline Phase 2 numbers from yesterday's abstract release. In the Duravelo-2 combination cohort, the optimal zelenectide dose plus pembrolizumab 200 mg every three weeks produced 65% ORR (17/26 evaluable patients) regardless of confirmation, with 58% BICR-confirmed ORR (15/26) at the 27-week cutoff in previously untreated locally advanced or metastatic urothelial cancer. An additional confirmed BICR response observed after the cutoff would bring the rate to 62%. The trial tested two dose schedules: 5 mg/m² weekly and 6 mg/m² two-weeks-on-one-week-off; the optimal dose moves forward in the Phase 3 expansion. Treatment retention was high and dose-limiting adverse events limited. The 65% Phase 2 ORR matches the 65% Phase 1 Duravelo-1 ORR (13/20) — pharmacology consistency across two different patient populations, an unusual durability signal for a peptide-drug conjugate.

#bicycle-therapeutics #duravelo-2 #zelenectide-pevedotin #urothelial-cancer #phase-2 #bicr-confirmed #asco-2026
Industry

Hims & Hers Prices Upsized $350M Convertible Notes Offering (May 18, Settling May 21): 0.00% Coupon Due 2032, Conversion Price $29.53/Share, Eucalyptus Acquisition Backing

Hims & Hers Health announced May 18 the pricing of an upsized $350M aggregate principal amount of 0.00% convertible senior notes due 2032, with settlement May 21. Initial conversion rate is 33.8590 shares of Class A common stock per $1,000 principal — a conversion price of approximately $29.53 per share, representing a 32.5% premium over the $22.29 close on May 18. The capped call cap price was set at approximately $50.15 per share (125% premium). Initial purchasers granted an option to buy up to an additional $52.5M in notes within 13 days. Proceeds support international expansion strategy and the proposed acquisition of Eucalyptus (Australian-based digital health platform with peptide and weight-management presence in Australia, UK, and Germany) expected to close mid-2026. The convertible structure preserves cash for the international rollout while the Novo Nordisk branded distribution partnership scales US Wegovy supply.

#hims-hers #convertible-notes #eucalyptus #international-expansion #350-million #telehealth
Clinical Trials

BriaCell ASCO 2026 Follow-On Press Release (May 22): Final Phase 2 Bria-IMT Median Overall Survival 16.6 Months in Heavily Pretreated Metastatic Breast Cancer With Phase 3 Formulation

BriaCell's formal post-ASCO 2026 press release Friday morning specified the headline number from yesterday's abstract release. Final Phase 2 median overall survival with Bria-IMT plus checkpoint inhibitor reached 16.6 months in heavily pretreated metastatic breast cancer patients using the Phase 3 formulation — a substantial improvement over historical post-ADC, post-CPI, post-CDK4/6-failure populations where median OS typically runs 8-10 months. The release also specified positive quality-of-life data from the ongoing Phase 3 study and biomarker analyses confirming the predictors of anti-cancer response observed in Phase 2 carry forward into the Phase 3 cohort. The three poster presentations plus three publication-only abstracts at ASCO 2026 (May 29-June 2) will detail 12- and 24-month survival, treatment tolerability, and circulating-tumor-cell biomarker work. The 16.6-month median OS sets the bar BriaCell needs to clear or beat in the ongoing Phase 3 to support its accelerated approval ambitions.

#briacell #bria-imt #metastatic-breast-cancer #phase-2-median-os #phase-3-formulation #asco-2026
Research

Nature Communications: AMPLiT Tool Identifies Antimicrobial Peptides From Ancient Human Gut Microbiomes (Coprolite Metagenomes)

A 2026 Nature Communications paper introduced AMPLiT — a tool for screening antimicrobial peptide candidates in metagenomic datasets — and applied it to human coprolite metagenomes (ancient stool samples). The team identified candidate AMPs from extinct gut-microbiome lineages that have functional activity against modern multidrug-resistant pathogens. The approach extends the AMP-discovery search space from contemporary microbial sequences to the much-larger reservoir of evolutionary AMPs encoded in ancient host-microbiome assemblies preserved in archaeological samples. The strategy joins the broader 2026 AI-AMP wave (ProteoGPT, CAMPER, the AI-driven AMP characterization paper in Scientific Reports) as an alternative source of novel chemistry against ESKAPE pathogens. The work positions ancient-DNA-based AMP discovery as a credible track alongside computational design.

#antimicrobial-peptides #amplit #ancient-microbiome #coprolite-metagenomes #nature-communications #esp-cape #amr
Research

Nature Communications (May 19): CRAB Engineered Peptide Inhibitors Block STIM1-ORAI Coupling in CRAC Channels, Enable Programmable Immune Control

A Nature Communications paper from a Texas A&M Health team published May 19 reported the engineering of genetically encoded calcium release-activated calcium channel (CRAC) inhibitory binders called CRABs — peptide inhibitors derived from the ORAI C-terminal tail that selectively interfere with STIM1-ORAI coupling. The plasma-membrane-anchored CRAB variant potently inhibits calcium influx and downstream NFAT signaling. The platform spans optogenetic (Opto-CRAB) and chemogenetic (Chemo-CRAB) variants for graded, real-time control of CRAC activity. In a zebrafish Stormorken syndrome model, CRABs rescued thrombocyte progenitor production. The therapeutic implication: a peptide-based adjustable brake on T-cell calcium signaling that could enable safer, more controllable immune cell therapies — CAR-T cytokine release moderation, autoimmune T-cell quenching, transplantation tolerance induction.

#crab #crac-channel #stim1-orai #calcium-signaling #immunotherapy #nature-communications #t-cell
Research

Journal of Peptide Science 2026: WDGL — A Tetrapeptide From Ulva Prolifera Activates Keap1-Nrf2 Antioxidant Pathway in Cellular Stress Models

A Journal of Peptide Science paper reported a novel four-amino-acid peptide WDGL (Trp-Asp-Gly-Leu) derived from Ulva prolifera — the green algae species responsible for major coastal blooms in East Asia. The peptide was identified through virtual screening of marine-derived peptide libraries, binds Keap1 at key residues, and activates the Nrf2 antioxidant pathway in cellular oxidative-stress models. In vitro pharmacokinetic profiling showed favorable properties for further development. The mechanistic rationale: Keap1-Nrf2 activation drives expression of antioxidant response element (ARE)-regulated genes including superoxide dismutase, catalase, and glutathione peroxidase, reducing reactive oxygen species (ROS) and oxidative damage. The WDGL work joins a small but growing literature on tetrapeptides as drug-like scaffolds — Aivocode's CAQK brain-injury tetrapeptide being the other May 2026 example. Marine-derived AMP and bioactive peptide discovery remains an underexplored chemistry frontier.

#wdgl #tetrapeptide #ulva-prolifera #keap1-nrf2 #marine-peptide #antioxidant #journal-of-peptide-science
Industry

Novo Nordisk Amycretin vs CagriSema Strategic Positioning After TRIUMPH-1 — Phase 3 AMAZE-12 vs REDEFINE 11 Read

Industry commentary May 22 framed Novo Nordisk's strategic response to retatrutide's TRIUMPH-1 readout as a two-track amylin strategy. CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) is the near-term play — Phase 3 REDEFINE-1 and REDEFINE-2 complete, FDA filing under review with decision expected late 2026, and Novo positioning the safety profile as the competitive edge after REDEFINE-4 missed non-inferiority versus tirzepatide 15 mg in February 2026. Amycretin (dual GLP-1/amylin agonist) is the long-term bet — AMAZE-12 Phase 3 began recruiting May 18 testing the dual agonist for weight maintenance, with Phase 1 results showing 22% weight loss at 36 weeks weekly subcutaneous and 13.1% at 12 weeks oral. The CagriSema higher-dose Phase 3 starts H2 2026; REDEFINE-11 reads out H1 2027. Combined, the amylin axis is structurally Novo's most direct response to Lilly's triple-agonist mechanism — adding amylin tone (slower gastric emptying, satiety persistence, weight-maintenance) rather than competing on glucagon-driven energy expenditure.

#novo-nordisk #amycretin #cagrisema #amaze-12 #redefine-11 #amylin-axis #competitive-positioning
Industry

Research and Markets Report (May 21): GLP-1 Agonists Weight Loss Drugs Market $15.5B in 2025 → $18.02B in 2026 (16.3% CAGR), Major Players Novo, Lilly, Pfizer

A May 21 Research and Markets report projected the global GLP-1 receptor agonist weight loss drug market expanding from $15.5B in 2025 to $18.02B in 2026 — a 16.3% compound annual growth rate. The forecast tracks through 2030 and 2035 across major players Novo Nordisk, Eli Lilly, and Pfizer, plus the growing oral GLP-1 segment (Wegovy pill, Foundayo, Structure Therapeutics' aleniglipron entering Phase 3). By 2020 roughly 4 million people were on GLP-1s; by 2026 that estimate has reached 30 million. The market data is the formal backdrop for the broader 2026 obesity-pharmacology conversation: GLP-1 alone is now larger than the 2024 oncology drug class's largest single product. The IQVIA peptide-CDMO capacity-build wave (Bachem, PolyPeptide, CordenPharma SPPS expansions through 2028) and the Lilly $4.5B Lebanon Indiana investment lean directly into the demand projection.

#glp-1-market #market-report #research-and-markets #novo-nordisk #eli-lilly #pfizer #market-forecast